文献速递脑血管病

阿加曲班治疗伴早期神经功能恶化的急性缺血性卒中患者:一项随机临床试验

Argatroban in Patients With Acute Ischemic Stroke With Early Neurological Deterioration: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2024-01-01

这项多中心、开放标签、盲法终点随机临床试验纳入628例伴早期神经功能恶化的急性缺血性卒中患者,比较阿加曲班联合标准治疗与单纯标准治疗的疗效。结果显示阿加曲班组90天良好功能结局(改良Rankin量表评分0-3分)比例为80.5%,对照组为73.3%,风险差7.2%(95%CI 0.6%-14.0%),风险比1.10(95%CI 1.01-1.20),P=0.04。

要点

  • 伴早期神经功能恶化的急性缺血性卒中患者,阿加曲班联合抗血小板治疗较单纯标准治疗改善90天功能结局。
  • 90天良好功能结局(改良Rankin量表评分0-3分):阿加曲班组240例(80.5%)vs 对照组222例(73.3%),风险差7.2%(95%CI 0.6%-14.0%),风险比1.10(95%CI 1.01-1.20),P=0.04。
  • 症状性颅内出血比例:阿加曲班组3/317(0.9%)vs 对照组2/272(0.7%),P=0.78。

核心结论

  • 在伴早期神经功能恶化的急性缺血性卒中患者中,阿加曲班联合抗血小板治疗较单纯标准治疗获得更好的90天功能结局。
  • 该试验为阿加曲班用于减少早期神经功能恶化患者残疾提供了证据支持。

研究设计与样本

  • 多中心、开放标签、盲法终点随机临床试验,于2020年4月4日至2022年7月31日开展,最终随访日期为2022年10月31日。
  • 纳入标准为成人急性缺血性卒中患者,早期神经功能恶化定义为症状发作后48小时内美国国立卫生研究院卒中量表评分增加2分或以上。
  • 共628例患者纳入研究(平均[标准差]年龄65[11.9]岁;男性400例[63.7%]),阿加曲班组314例(50%),对照组314例(50%)。
  • 18例撤回知情同意,1例重复随机化,8例失访;601例纳入意向性治疗分析,564例纳入符合方案分析(阿加曲班组6例、对照组31例未遵循完整方案)。
  • 两组均接受基于指南的标准治疗,包括口服单联或双联抗血小板治疗;阿加曲班组额外接受静脉阿加曲班7天(前2天以60 mg/日持续输注,后5天以20 mg/日输注)。

主要发现

  • 90天良好功能结局(改良Rankin量表评分0-3分)患者数:阿加曲班组240例(80.5%)vs 对照组222例(73.3%),风险差7.2%(95%CI 0.6%-14.0%),风险比1.10(95%CI 1.01-1.20),P=0.04。
  • 症状性颅内出血比例:阿加曲班组3/317(0.9%)vs 对照组2/272(0.7%),P=0.78。

临床怎么用

  • 作者认为,在伴早期神经功能恶化的急性缺血性卒中患者中,阿加曲班联合抗血小板治疗可获得更好的90天功能结局。
  • 该试验为支持使用阿加曲班减少早期神经功能恶化患者残疾提供了证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The effect of argatroban in patients with acute ischemic stroke (AIS) and early neurological deterioration (END) is unknown. OBJECTIVE: To assess the efficacy of argatroban for END in AIS. DESIGN, SETTING, AND PARTICIPANTS: This open-label, blinded-end point, randomized clinical trial was conducted from April 4, 2020, through July 31, 2022. The date of final follow-up was October 31, 2022. This was a multicenter trial. Eligible patients were adults with AIS who experienced END, which was defined as an increase of 2 or more points on the National Institutes of Health Stroke Scale within 48 hours from symptom onset. Patients who withdrew consent, experienced duplicate randomization, or were lost to follow-up were excluded from the study. INTERVENTIONS: Patients were randomly assigned to the argatroban group and control group within 48 hours of symptom onset. Both groups received standard therapy based on guidelines, including oral mono or dual antiplatelet therapy. The argatroban group received intravenous argatroban for 7 days (continuous infusion at a dose of 60 mg per day for 2 days, followed by 20 mg per day for 5 days) in addition to standard therapy. MAIN OUTCOME AND MEASURE: The primary end point was good functional outcome at 90 days, defined as a modified Rankin Scale score of 0 to 3. RESULTS: A total of 628 patients (mean [SD] age, 65 [11.9] years; 400 male [63.7%]) were included in this study (argatroban group, 314 [50%] and control group, 314 [50%]). Of these, 18 withdrew consent, 1 had duplicate randomization, and 8 were lost to follow-up. A total of 601 patients with stroke were included in the intention-to-treat analysis. Finally, 564 patients were included in the per-protocol analysis as 6 participants in the argatroban group and 31 participants in the control group did not follow the complete protocol. The number of patients with good functional outcome at 90 days was 240 (80.5%) in the argatroban group and 222 (73.3%) in the control group (risk difference, 7.2%; 95% CI, 0.6%-14.0%; risk ratio, 1.10; 95% CI, 1.01-1.20; P = .04). The proportion of symptomatic intracranial hemorrhage was 3 of 317 (0.9%) in the argatroban group and 2 of 272 (0.7%) in the control group (P = .78). CONCLUSIONS AND RELEVANCE: Among patients with AIS with END, treatment with argatroban and antiplatelet therapy resulted in a better functional outcome at 90 days. This trial provided evidence to support the use of argatroban in reducing disability for patients with END. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04275180.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Zhang X, Zhong W, Xue R, et al. Argatroban in Patients With Acute Ischemic Stroke With Early Neurological Deterioration: A Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 38190136. doi:10.1001/jamaneurol.2023.5093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。